Multiple drugsInefficacy following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1882卷 / 1期

关键词：

D O I：

10.1007/s40278-021-05805-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：338 / 338

相关论文

共 50 条

[21] FavipiravirNephrotoxicity following off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 283 - 283
[22] NivolumabFever following off-label use: case report
[J]. Reactions Weekly, 2016, 1601 (1) : 186 - 186
[23] TocilizumabAnaphylaxis following off-label use: case report
[J]. Reactions Weekly, 2021, 1865 (1) : 397 - 397
[24] RituximabPancytopenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1807 (1) : 176 - 176
[25] MethotrexateSteatohepatitis following off-label use: case report
[J]. Reactions Weekly, 2019, 1768 (1) : 225 - 225
[26] RivoceranibNeurotoxicity following an off-label use: case report
[J]. Reactions Weekly, 2018, 1702 (1) : 232 - 232
[27] AzacitidineDiarrhoea following off-label use: case report
[J]. Reactions Weekly, 2019, 1736 (1) : 48 - 48
[28] RisdiplamPneumonia following off-label use: case report
[J]. Reactions Weekly, 2023, 1950 (1) : 348 - 348
[29] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 111 - 111
[30] TocilizumabNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2021, 1853 (1) : 446 - 446

← 1 2 3 4 5 →